Factors Affecting the Absorption of Midazolam to the Extracorporeal Membrane Oxygenation Circuit.

Sedatives are administered during extracorporeal membrane oxygenation (ECMO) therapy to ensure patient safety, reduce the metabolic rate and correct the oxygen supply-demand balance. However, the concentrations of sedatives can be decreased due to absorption into the circuit. This study examined factors affecting the absorption of a commonly used sedative, midazolam (MDZ). Using multiple ex vivo simulation models, three factors that may influence MDZ levels in the ECMO circuit were examined: polyvinyl chloride (PVC) tubing in the circuit, use of a membrane oxygenator in the circuit, and heparin coating of the circuit. We also assessed changes in drug concentration when MDZ was re-injected in a circuit. The MDZ level decreased to approximately 60% of the initial concentration in simulated circuits within the first 30 minutes. The strongest factor in this phenomenon was contact with the PVC tubing. Membrane oxygenator use tended to increase MDZ loss, whereas heparin circuit coating had no influence on MDZ absorption. Similar results were obtained when a second dose of MDZ was injected to the second-use circuits.

[1]  P. Leprince,et al.  Propofol, midazolam, vancomycin and cyclosporine therapeutic drug monitoring in extracorporeal membrane oxygenation circuits primed with whole human blood , 2015, Critical Care.

[2]  J. Fraser,et al.  Pharmacokinetic changes in patients receiving extracorporeal membrane oxygenation. , 2012, Journal of critical care.

[3]  J. Fraser,et al.  Sedation during extracorporeal membrane oxygenation-why more is less. , 2012, Anaesthesia and Intensive Care.

[4]  A. Combes,et al.  Impact of Extracorporeal Membrane Oxygenation and Continuous Venovenous Hemodiafiltration on the Pharmacokinetics of Oseltamivir Carboxylate in Critically Ill Patients With Pandemic (H1N1) Influenza , 2012, Therapeutic drug monitoring.

[5]  D. Tibboel,et al.  Determinants of drug absorption in different ECMO circuits , 2010, Intensive Care Medicine.

[6]  L. Chicoine,et al.  Modified surface coatings and their effect on drug adsorption within the extracorporeal life support circuit. , 2010, The journal of extra-corporeal technology.

[7]  D. Tibboel,et al.  Population Pharmacokinetics of Midazolam and Its Metabolites during Venoarterial Extracorporeal Membrane Oxygenation in Neonates , 2010, Clinical pharmacokinetics.

[8]  A. Combes,et al.  Oseltamivir carboxylate accumulation in a patient treated by haemodiafiltration and extracorporeal membrane oxygenation , 2010, Intensive Care Medicine.

[9]  K. Senshu,et al.  Study on Drug Sorption of Polyvinyl Chloride-Infusion Line Containing Tris (2-ethylhexyl) trimellitate as the Plasticizer and Release Behavior of the Plasticizer , 2010 .

[10]  J. Arnold,et al.  Potential drug sequestration during extracorporeal membrane oxygenation: results from an ex vivo experiment , 2007, Intensive Care Medicine.

[11]  K. Allegaert,et al.  Pharmacotherapy during neonatal extracorporeal membrane oxygenation: toward an evidence-based approach , 2007, Critical care.

[12]  G. Annich,et al.  Sedative clearance during extracorporeal membrane oxygenation , 2005, Perfusion.

[13]  Laurance Lequier,et al.  Extracorporeal Life Support in Pediatric and Neonatal Critical Care: A Review , 2004, Journal of intensive care medicine.

[14]  H. Mulla,et al.  Plasma Concentrations of Midazolam in Neonates Receiving Extracorporeal Membrane Oxygenation , 2003, ASAIO journal.

[15]  M. Buck.  Pharmacokinetic Changes During Extracorporeal Membrane Oxygenation , 2003, Clinical pharmacokinetics.

[16]  B. Short,et al.  The current status of neonatal extracorporeal membrane oxygenation. , 2000, Seminars in perinatology.

[17]  B. Short,et al.  Citrobacter Sepsis and Severe Newborn Respiratory Failure Supported With Extracorporeal Membrane Oxygenation , 2000, Journal of Perinatology.

[18]  H. Mulla,et al.  In vitro evaluation of sedative drug losses during extracorporeal membrane oxygenation , 2000, Perfusion.

[19]  H P Wendel,et al.  Coating-techniques to improve the hemocompatibility of artificial devices used for extracorporeal circulation. , 1999, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[20]  P. Rosenberg,et al.  Coating of extracorporeal circuit with heparin does not prevent sequestration of propofol in vitro. , 1999, British journal of anaesthesia.

[21]  M C Davies,et al.  Uptake of drugs by catheters: the influence of the drug molecule on sorption by polyurethane catheters. , 1996, Biomaterials.

[22]  J. Fackler,et al.  The impact of extracorporeal membrane oxygenation on survival in pediatric patients with acute respiratory failure. Pediatric Critical Care Study Group. , 1996, Critical care medicine.

[23]  G. Koren,et al.  Preliminary Studies of the Effects of Extracorporeal Membrane Oxygenator on the Disposition of Common Pediatric Drugs , 1993, Therapeutic drug monitoring.

[24]  S. Nakajima,et al.  The Effect of pH in the Solutions on the Sorption of Midazolam into a Plastic Container or an Administration Set. , 1992 .

[25]  R H Bartlett,et al.  Extracorporeal life support for cardiopulmonary failure. , 1990, Current problems in surgery.

[26]  D. Rosen,et al.  In vitro variability in fentanyl absorption by different membrane oxygenators. , 1990, Journal of cardiothoracic anesthesia.